Developer docs
API playgroundTry for free, no card

Search company profiles

MoCA Cognition

Full company profile

uuid000a5ib

Namestring
MoCA Cognition
Legal namestring
MoCA Test Inc.
Company typeenum
Private
Founded yearint
2005
Descriptiontext

MoCA Cognition (legally MoCA Test Inc.) is a privately held Canadian health technology company headquartered in Greenfield Park, Quebec, that develops, distributes, and licenses the Montreal Cognitive Assessment (MoCA) — a brief 30-question cognitive screening tool validated for early detection of mild cognitive impairment (MCI). The company was founded by neurologist Dr. Ziad Nasreddine, who developed MoCA during his clinical work, validated the test in 2000, and officially published it in 2005. MoCA Cognition serves healthcare professionals (nurses, primary care and specialty physicians, occupational therapists, speech-language pathologists, psychologists, and researchers), pharmaceutical companies, and consumer end-users, operating alongside an affiliated MoCA Memory Clinic in the Montreal area that serves more than 2,000 patients annually.

The company's product portfolio includes the paper-based MoCA (PDF downloads), the Digital MoCA delivered via the MoCA Duo tablet application on iOS and Android (which provides automated administration and scoring, machine-learning-enhanced accuracy, and EHR integration), the MoCA Training and Certification Program (mandatory for paper-based use since September 2019 with biennial recertification), specialized variants (MoCA Basic for low-education populations, MoCA Blind for visually impaired patients, alternate versions 8.2 and 8.3 to mitigate memorization effects), and the consumer-facing MoCA-XpressO self-assessment platform launched in March 2024. The MoCA test is available in more than 100 languages and dialects, has been validated in more than 7,000 peer-reviewed studies cited across 26,000+ articles, and was named the most widely used MCI detection tool by the 2021 World Alzheimer Report and ranked #1 among 53 cognitive screening tests by a 2023 global Delphi consensus.

MoCA Cognition operates a hybrid revenue model: the MoCA app and paper-based test are free for individual healthcare professionals and academia, while paid streams include professional organizational subscriptions (approximately USD 10 per month per evaluator), training and certification packages for organizations, and multi-year commercial and pharmaceutical licensing agreements. Distribution combines direct website downloads, major app stores, and partner-led international rollout — most notably a March 2026 launch of a Japanese version of MoCA-XpressO via Teoria Technologies Co., Ltd. (Eisai Group), targeting Japan's estimated 5 million people with MCI. Data practices comply with GDPR (Article 9) and Canadian PIPEDA. The company is founder-controlled with no disclosed institutional investors, parent company, or subsidiaries.

Short descriptiontext

MoCA Cognition (MoCA Test Inc.) develops and licenses the Montreal Cognitive Assessment (MoCA), a 30-question cognitive screening tool with 90% sensitivity for mild cognitive impairment, serving healthcare professionals, researchers, pharmaceutical companies, and consumers globally via paper, mobile, and self-assessment formats.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cognitive screening tools, digital health assessments, neurological diagnostic software, memory clinic solutions, clinical certification programs
Industry2 codes
PRIMARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYEDAGADAJ
Diagnostic & Adaptive Assessment Content (Skills/Readiness)
Education/Educational Publishing & Learning Content/Assessment, Testing & Exam Prep Publishing
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Software Publishers5132
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Prepackaged Software7372
Product category
Cognitive Assessment Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Professional App Subscription
TypeSubscription Recurring
Description

MoCA Duo mobile application is free for healthcare professionals and academia, with a professional subscription paid tier for organizations requiring enhanced features or multi-user management.

2Training and Certification Program
TypeSubscription Recurring
Description

Training and certification for administering and scoring the MoCA test is available for purchase by organizations. Free for full-time students, faculty, academic researchers, and employees of publicly operated healthcare institutions upon providing proof of eligibility.

mocacognition.com
3Commercial Licensing
TypeLicensing Royalties
Description

Written permission and licensing agreements are required for commercial entities and pharmaceutical companies wishing to use, reproduce, or distribute the MoCA test. Clinical use by universities, foundations, hospitals, and public health institutes is free without permission but requires licensing if funded by a commercial entity or pharma.

mocacognition.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details5 tiers
1Free tier for individual healthcare professionals and academia
ModelFreemium
Notes

The MoCA App is free for healthcare professionals and academia. This includes digital MoCA administration, automated scoring, and EHR data upload capability. The paper-based MoCA is also free to download for healthcare professionals.

2Training and Certification — Free for eligible users
ModelFreemium
Notes

Training and certification is free for full-time (a) students, faculty members, professors, and academic researchers, and (b) employees of publicly operated healthcare institutions, upon providing acceptable evidence of academic status or affiliation.

mocacognition.com
3Training and Certification — Organizational purchase
ModelSubscriptionBilling cadenceAnnual
Notes

Training packages are available for purchase for organizations. Contact sales for organizational pricing.

mocacognition.com
4MoCA App — Professional subscription
ModelPer seatBilling cadenceMonthly
Notes

The MoCA App costs $10 USD per month, per evaluator (approximately), for professional/organizational use. Exact pricing for enterprise multi-user packages requires a quote.

mocacognition.com
5Commercial/Pharma Licensing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

MoCA may be used by commercial entities and pharma WITH prior written permission and a licensing agreement. Pricing is negotiated through a commercial licensing agreement. Universities and publicly operated healthcare institutions require licensing if funded by commercial or pharma sources.

mocacognition.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1MoCA-XpressO
Description

Digital self-assessment platform for cognitive health launched March 2024, enables users to assess risk of cognitive decline in 5 minutes

alzint.org
+1 more record
Core offering1 text field

MoCA Cognition develops, distributes, and licenses the Montreal Cognitive Assessment (MoCA) — a copyrighted, validated 30-question cognitive screening tool for early detection of mild cognitive impairment (MCI) — available in paper PDF format and as the MoCA Duo tablet app with automated scoring and EHR integration. The company also sells a mandatory Training and Certification program for clinicians (free for students, faculty, and publicly operated healthcare institution employees) and operates the consumer-facing MoCA-XpressO digital self-assessment platform launched in March 2024.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 90% sensitivity for detecting mild cognitive impairment (vs. 18% for MMSE)
+3 more records
Product overview1 text field

MoCA Cognition offers a portfolio of cognitive assessment products centered on the MoCA (Montreal Cognitive Assessment) test — a brief 30-question screening tool for mild cognitive impairment (MCI) with 90% sensitivity. The core offerings comprise the paper-based MoCA (PDF downloads) and the Digital MoCA via the MoCA Duo tablet app. The digital app includes automated administration and scoring and integrates with EHR systems. Supporting products include the MoCA Training and Certification Program (mandatory for paper-based use, recommended for digital), and specialized variants such as MoCA Basic (for low-education populations) and MoCA Blind (for visually impaired users). Alternate versions (8.2, 8.3) are available for repeated administrations. A new consumer-facing self-assessment tool, MoCA-XpressO, was launched in March 2024 for the general public. The company is headquartered in Greenfield Park, Quebec, Canada, and is led by Dr. Ziad Nasreddine.

Product and service4 records
1Digital MoCA (MoCA Duo App)
CategoryDigital Cognitive Assessment Software
Description

Tablet-based digital MoCA assessment tool for healthcare organizations and researchers with mobile tablet capability; delivers automated scoring, sub-scores, and time-to-completion metrics, and can upload results to EHR systems. Free for healthcare professionals and academia, with a paid professional subscription at ~USD 10/evaluator/month for organizations needing multi-user management.

2MoCA-XpressO
CategoryConsumer Cognitive Self-Assessment Platform
Description

Digital self-assessment platform for cognitive health targeting the general public, enabling risk assessment of cognitive decline in approximately 5 minutes based on the internationally recognized MoCA theory. Accessible via mocaxpresso.com / portal.mocacognition.com without needing a healthcare professional.

3MoCA Training and Certification Program
CategoryClinical Training and Certification Service
Description

Official standardized training and certification program for administering and scoring the MoCA test, including sub-score interpretation. Mandatory for paper-based clinical, research, and educational use and recommended for Digital MoCA; free for full-time students, faculty, academic researchers, and employees of publicly operated healthcare institutions upon providing proof of eligibility.

4MoCA Commercial Licensing
CategoryIntellectual Property Licensing
Description

Formal written licensing and permission grants allowing commercial entities and pharmaceutical companies to use, reproduce, or distribute the MoCA test (and digital derivatives) within clinical research, drug development, or commercial programs. Universities, foundations, hospitals, and public health institutes can use MoCA clinically/academically without permission but require licensing if funded by a commercial entity or pharma source.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Teoria Technologies Co., Ltd. (Eisai Group)
Strategic tierCoreTypeGTM or Marketing Partner
Description

Teoria Technologies Co., Ltd., a member of the Eisai Group, launched a Japanese version of MoCA-XpressO, a digital self-check tool for cognitive function based on the MoCA theory. This partnership addresses Japan's growing need for early dementia detection amid an estimated 5 million people with Mild Cognitive Impairment. The company plans to expand adoption through partnerships with local governments and integration into corporate health check programs.

prtimes.jp
2ADI (Alzheimer's Disease International)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

ADI (Alzheimer's Disease International) published a case study highlighting MoCA Cognition's MoCA-XpressO digital self-assessment platform for cognitive health. The case study demonstrates how digital self-assessment tools can normalize conversations about cognitive health and encourage earlier medical consultation, validating MoCA-XpressO's role in population-level cognitive health screening.

alzint.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Ziad Nasreddine completed a fellowship in cognitive neurology and neurobehavior at UCLA. UCLA collaborators Jeffrey Saver and Mario Mendez are acknowledged contributors to MoCA's development and validation. UCLA-based research has contributed to the validation of MoCA across multiple clinical conditions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Serge Gauthier from McGill University is listed as a key collaborator in MoCA's development, contributing to the validation and clinical adoption of the cognitive assessment tool in academic and clinical settings.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Jeffrey Cummings from the Cleveland Clinic is listed as a collaborator in MoCA's development. Cummings is a renowned expert in Alzheimer's disease and dementia research, lending clinical and research credibility to the MoCA assessment tool.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Howard Chertkow from Baycrest is a collaborator on the MoCA project. Baycrest is a leading academic health sciences center focused on aging and brain health, contributing to the clinical validation and research behind MoCA.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Raymonde Labrecque and Simon Charbonneau from CHUM are listed as collaborators. Their contributions support the French-language validation and clinical research applications of MoCA in Quebec and francophone populations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Natalie Phillips from Concordia University is a recognized contributor to MoCA's research and validation, supporting cognitive assessment research and normative data development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Isabelle Rouleau from UQAM is listed as a collaborator, supporting MoCA's academic research and development in Quebec's university ecosystem.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Victor Whitehead from the Jewish General Hospital and the Mémoire clinic are collaborators, contributing to clinical validation and patient care applications of MoCA in hospital settings.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Vladimir Hachinski from Western University is a collaborator, contributing expertise in vascular cognitive impairment and stroke-related cognitive assessment to MoCA's clinical development.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Digital cognitive assessment and lifestyle program for early detection of cognitive decline, targeting a similar consumer/professional audience as MoCA-XpressO.

TypeDirect peer
Description

FDA-cleared digital cognitive assessment platform using AR/AI on smartphones, competing with MoCA's digital app for early detection of MCI and Alzheimer's.

TypeDirect peer
Description

Digital cognitive assessment platform using tablet-based tests and AI to detect cognitive impairment, directly competing with MoCA Duo and XpressO in primary care and consumer brain health.

TypeEmerging player
Description

Speech-based digital biomarker platform for cognitive impairment assessment, intersecting with MoCA's mission of early MCI detection through a different modality (voice vs. questionnaire).

TypeDirect peer
Description

Offers computerized cognitive testing across clinical trials, healthcare, and research with comparable sensitivity/standardization claims to MoCA, serving overlapping pharma and academic customers.

TypeEmerging player
Description

Cognitive training and assessment company with clinically validated brain training exercises, partially overlapping with MoCA's cognitive health screening audience.

TypeDirect peer
Description

Digital cognitive assessment and care management platform for clinicians, providing a tablet-based alternative to MoCA in primary care and neurology workflows.

TypeOthers
Description

Provides tau PET imaging biomarkers for Alzheimer's disease research and clinical trials; complementary to MoCA as a screening-plus-imaging diagnostic pathway for the same patient population.

TypeDirect peer
Description

Provides computerized cognitive testing (CANTAB) for clinical trials and healthcare, directly competing with MoCA in digital cognitive assessment for research and clinical settings.

TypeDirect peer
Description

Online cognitive assessment platform for healthcare providers and researchers, offering computerized tests comparable in target use case to MoCA's professional offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MoCA Cognition

Cognitive Assessment Softwaremocacognition.com

MoCA Cognition (MoCA Test Inc.) develops and licenses the Montreal Cognitive Assessment (MoCA), a 30-question cognitive screening tool with 90% sensitivity for mild cognitive impairment, serving healthcare professionals, researchers, pharmaceutical companies, and consumers globally via paper, mobile, and self-assessment formats.

What MoCA Cognition does

MoCA Cognition (legally MoCA Test Inc.) is a privately held Canadian health technology company headquartered in Greenfield Park, Quebec, that develops, distributes, and licenses the Montreal Cognitive Assessment (MoCA) — a brief 30-question cognitive screening tool validated for early detection of mild cognitive impairment (MCI). The company was founded by neurologist Dr. Ziad Nasreddine, who developed MoCA during his clinical work, validated the test in 2000, and officially published it in 2005. MoCA Cognition serves healthcare professionals (nurses, primary care and specialty physicians, occupational therapists, speech-language pathologists, psychologists, and researchers), pharmaceutical companies, and consumer end-users, operating alongside an affiliated MoCA Memory Clinic in the Montreal area that serves more than 2,000 patients annually.

The company's product portfolio includes the paper-based MoCA (PDF downloads), the Digital MoCA delivered via the MoCA Duo tablet application on iOS and Android (which provides automated administration and scoring, machine-learning-enhanced accuracy, and EHR integration), the MoCA Training and Certification Program (mandatory for paper-based use since September 2019 with biennial recertification), specialized variants (MoCA Basic for low-education populations, MoCA Blind for visually impaired patients, alternate versions 8.2 and 8.3 to mitigate memorization effects), and the consumer-facing MoCA-XpressO self-assessment platform launched in March 2024. The MoCA test is available in more than 100 languages and dialects, has been validated in more than 7,000 peer-reviewed studies cited across 26,000+ articles, and was named the most widely used MCI detection tool by the 2021 World Alzheimer Report and ranked #1 among 53 cognitive screening tests by a 2023 global Delphi consensus.

MoCA Cognition operates a hybrid revenue model: the MoCA app and paper-based test are free for individual healthcare professionals and academia, while paid streams include professional organizational subscriptions (approximately USD 10 per month per evaluator), training and certification packages for organizations, and multi-year commercial and pharmaceutical licensing agreements. Distribution combines direct website downloads, major app stores, and partner-led international rollout — most notably a March 2026 launch of a Japanese version of MoCA-XpressO via Teoria Technologies Co., Ltd. (Eisai Group), targeting Japan's estimated 5 million people with MCI. Data practices comply with GDPR (Article 9) and Canadian PIPEDA. The company is founder-controlled with no disclosed institutional investors, parent company, or subsidiaries.

MoCA Cognition firmographics

Firmographics
Name
MoCA Cognition
Legal name
MoCA Test Inc.
Website
https://mocacognition.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
MoCA Cognition (MoCA Test Inc.) develops and licenses the Montreal Cognitive Assessment (MoCA), a 30-question cognitive screening tool with 90% sensitivity for mild cognitive impairment, serving healthcare professionals, researchers, pharmaceutical companies, and consumers globally via paper, mobile, and self-assessment formats.
Ownership category
akta.pro rank

MoCA Cognition industry classification

Industry
Product category
Cognitive Assessment Software
NAICS
Medical and Diagnostic Laboratories (6215), Software Publishers (5132)
SIC
Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYEDAGADAJ
Diagnostic & Adaptive Assessment Content (Skills/Readiness)
Education/Educational Publishing & Learning Content/Assessment, Testing & Exam Prep Publishing

Keywords

  • Cognitive screening tools
  • Digital health assessments
  • Neurological diagnostic software
  • Memory clinic solutions
  • Clinical certification programs

Where MoCA Cognition is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

MoCA Cognition business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Professional App Subscription: MoCA Duo mobile application is free for healthcare professionals and academia, with a professional subscription paid tier for organizations requiring enhanced features or multi-user management.
  2. Training and Certification Program: Training and certification for administering and scoring the MoCA test is available for purchase by organizations. Free for full-time students, faculty, academic researchers, and employees of publicly operated healthcare institutions upon providing proof of eligibility.
  3. Commercial Licensing: Written permission and licensing agreements are required for commercial entities and pharmaceutical companies wishing to use, reproduce, or distribute the MoCA test. Clinical use by universities, foundations, hospitals, and public health institutes is free without permission but requires licensing if funded by a commercial entity or pharma.

Pricing tiers

ModelBillingPrice
Freemium—Free tier for individual healthcare professionals and academia
Freemium—Training and Certification — Free for eligible users
SubscriptionAnnualTraining and Certification — Organizational purchase
Per seatMonthlyMoCA App — Professional subscription
SubscriptionMulti-year contractCommercial/Pharma Licensing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

MoCA Cognition product offering

Product offering

Core offering

MoCA Cognition develops, distributes, and licenses the Montreal Cognitive Assessment (MoCA) — a copyrighted, validated 30-question cognitive screening tool for early detection of mild cognitive impairment (MCI) — available in paper PDF format and as the MoCA Duo tablet app with automated scoring and EHR integration. The company also sells a mandatory Training and Certification program for clinicians (free for students, faculty, and publicly operated healthcare institution employees) and operates the consumer-facing MoCA-XpressO digital self-assessment platform launched in March 2024.

Product overview

MoCA Cognition offers a portfolio of cognitive assessment products centered on the MoCA (Montreal Cognitive Assessment) test — a brief 30-question screening tool for mild cognitive impairment (MCI) with 90% sensitivity. The core offerings comprise the paper-based MoCA (PDF downloads) and the Digital MoCA via the MoCA Duo tablet app. The digital app includes automated administration and scoring and integrates with EHR systems. Supporting products include the MoCA Training and Certification Program (mandatory for paper-based use, recommended for digital), and specialized variants such as MoCA Basic (for low-education populations) and MoCA Blind (for visually impaired users). Alternate versions (8.2, 8.3) are available for repeated administrations. A new consumer-facing self-assessment tool, MoCA-XpressO, was launched in March 2024 for the general public. The company is headquartered in Greenfield Park, Quebec, Canada, and is led by Dr. Ziad Nasreddine.

Differentiator

Problem solved

Functional benefit

Brands

  • MoCA-XpressO: Digital self-assessment platform for cognitive health launched March 2024, enables users to assess risk of cognitive decline in 5 minutes
  • MoCA Duo

Products and services

  • Digital MoCA (MoCA Duo App) Tablet-based digital MoCA assessment tool for healthcare organizations and researchers with mobile tablet capability; delivers automated scoring, sub-scores, and time-to-completion metrics, and can upload results to EHR systems. Free for healthcare professionals and academia, with a paid professional subscription at ~USD 10/evaluator/month for organizations needing multi-user management.
  • MoCA-XpressO Digital self-assessment platform for cognitive health targeting the general public, enabling risk assessment of cognitive decline in approximately 5 minutes based on the internationally recognized MoCA theory. Accessible via mocaxpresso.com / portal.mocacognition.com without needing a healthcare professional.
  • MoCA Training and Certification Program Official standardized training and certification program for administering and scoring the MoCA test, including sub-score interpretation. Mandatory for paper-based clinical, research, and educational use and recommended for Digital MoCA; free for full-time students, faculty, academic researchers, and employees of publicly operated healthcare institutions upon providing proof of eligibility.
  • MoCA Commercial Licensing Formal written licensing and permission grants allowing commercial entities and pharmaceutical companies to use, reproduce, or distribute the MoCA test (and digital derivatives) within clinical research, drug development, or commercial programs. Universities, foundations, hospitals, and public health institutes can use MoCA clinically/academically without permission but require licensing if funded by a commercial entity or pharma source.

Quantifiable outcome

  • 90% sensitivity for detecting mild cognitive impairment (vs. 18% for MMSE)
  • +3 more outcomes

Companies that use MoCA Cognition

Customer profile

Named customers2 records

Ideal customer profiles4 records

MoCA Cognition technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

MoCA Cognition partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, flagship and minor.

  • Teoria Technologies Co., Ltd. (Eisai Group)coreGTM or Marketing PartnerTeoria Technologies Co., Ltd., a member of the Eisai Group, launched a Japanese version of MoCA-XpressO, a digital self-check tool for cognitive function based on the MoCA theory. This partnership addresses Japan's growing need for early dementia detection amid an estimated 5 million people with Mild Cognitive Impairment. The company plans to expand adoption through partnerships with local governments and integration into corporate health check programs.
  • ADI (Alzheimer's Disease International)flagshipStrategic or Co-development PartnerADI (Alzheimer's Disease International) published a case study highlighting MoCA Cognition's MoCA-XpressO digital self-assessment platform for cognitive health. The case study demonstrates how digital self-assessment tools can normalize conversations about cognitive health and encourage earlier medical consultation, validating MoCA-XpressO's role in population-level cognitive health screening.
  • UCLA (University of California, Los Angeles)coreStrategic or Co-development PartnerDr. Ziad Nasreddine completed a fellowship in cognitive neurology and neurobehavior at UCLA. UCLA collaborators Jeffrey Saver and Mario Mendez are acknowledged contributors to MoCA's development and validation. UCLA-based research has contributed to the validation of MoCA across multiple clinical conditions.
  • McGill University (Serge Gauthier)coreStrategic or Co-development PartnerSerge Gauthier from McGill University is listed as a key collaborator in MoCA's development, contributing to the validation and clinical adoption of the cognitive assessment tool in academic and clinical settings.
  • Cleveland Clinic (Jeffrey Cummings)coreStrategic or Co-development PartnerJeffrey Cummings from the Cleveland Clinic is listed as a collaborator in MoCA's development. Cummings is a renowned expert in Alzheimer's disease and dementia research, lending clinical and research credibility to the MoCA assessment tool.
  • Baycrest Health Sciences (Howard Chertkow)coreStrategic or Co-development PartnerHoward Chertkow from Baycrest is a collaborator on the MoCA project. Baycrest is a leading academic health sciences center focused on aging and brain health, contributing to the clinical validation and research behind MoCA.
  • CHUM (Centre hospitalier de l'Université de Montréal)minorStrategic or Co-development PartnerRaymonde Labrecque and Simon Charbonneau from CHUM are listed as collaborators. Their contributions support the French-language validation and clinical research applications of MoCA in Quebec and francophone populations.
  • Concordia University (Natalie Phillips)minorStrategic or Co-development PartnerNatalie Phillips from Concordia University is a recognized contributor to MoCA's research and validation, supporting cognitive assessment research and normative data development.
  • UQAM (Université du Québec à Montréal)minorStrategic or Co-development PartnerIsabelle Rouleau from UQAM is listed as a collaborator, supporting MoCA's academic research and development in Quebec's university ecosystem.
  • Jewish General Hospital / Mémoire — Hôpital générale juifminorStrategic or Co-development PartnerVictor Whitehead from the Jewish General Hospital and the Mémoire clinic are collaborators, contributing to clinical validation and patient care applications of MoCA in hospital settings.
  • Western University (Vladimir Hachinski)minorStrategic or Co-development PartnerVladimir Hachinski from Western University is a collaborator, contributing expertise in vascular cognitive impairment and stroke-related cognitive assessment to MoCA's clinical development.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

MoCA Cognition competitors and assessment

Company assessment

Emerging players

  • Neurotrack: Digital cognitive assessment and lifestyle program for early detection of cognitive decline, targeting a similar consumer/professional audience as MoCA-XpressO.
  • Winterlight Labs: Speech-based digital biomarker platform for cognitive impairment assessment, intersecting with MoCA's mission of early MCI detection through a different modality (voice vs. questionnaire).
  • Posit Science (BrainHQ): Cognitive training and assessment company with clinically validated brain training exercises, partially overlapping with MoCA's cognitive health screening audience.

Direct peers

  • Altoida: FDA-cleared digital cognitive assessment platform using AR/AI on smartphones, competing with MoCA's digital app for early detection of MCI and Alzheimer's.
  • Linus Health: Digital cognitive assessment platform using tablet-based tests and AI to detect cognitive impairment, directly competing with MoCA Duo and XpressO in primary care and consumer brain health.
  • Cogstate: Offers computerized cognitive testing across clinical trials, healthcare, and research with comparable sensitivity/standardization claims to MoCA, serving overlapping pharma and academic customers.
  • BrainCheck: Digital cognitive assessment and care management platform for clinicians, providing a tablet-based alternative to MoCA in primary care and neurology workflows.
  • Cambridge Cognition: Provides computerized cognitive testing (CANTAB) for clinical trials and healthcare, directly competing with MoCA in digital cognitive assessment for research and clinical settings.
  • Creyos (Cambridge Brain Sciences): Online cognitive assessment platform for healthcare providers and researchers, offering computerized tests comparable in target use case to MoCA's professional offering.

Others

  • Cerveau Technologies: Provides tau PET imaging biomarkers for Alzheimer's disease research and clinical trials; complementary to MoCA as a screening-plus-imaging diagnostic pathway for the same patient population.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

MoCA Cognition social profiles

Digital presence

MoCA Cognition compliance and trust

Trust signal

Compliance2 records

MoCA Cognition financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MoCA Cognition leadership team

Management profile

Number of profiles

Profiles1 record

MoCA Cognition funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MoCA Cognition M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MoCA Cognition

What does MoCA Cognition do?

MoCA Cognition develops, distributes, and licenses the Montreal Cognitive Assessment (MoCA) — a copyrighted, validated 30-question cognitive screening tool for early detection of mild cognitive impairment (MCI) — available in paper PDF format and as the MoCA Duo tablet app with automated scoring and EHR integration. The company also sells a mandatory Training and Certification program for clinicians (free for students, faculty, and publicly operated healthcare institution employees) and operates the consumer-facing MoCA-XpressO digital self-assessment platform launched in March 2024.

Is MoCA Cognition a public or private company?

MoCA Cognition is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MoCA Cognition founded?

MoCA Cognition was founded in 2005. It employs 51 to 100 people.

Where is MoCA Cognition based?

MoCA Cognition is headquartered in Montreal, Canada, in the North America region.

How does MoCA Cognition make money?

Three revenue lines are on record. Professional App Subscription is the primary driver. The others are training and Certification Program and commercial Licensing.

Who are MoCA Cognition's main competitors?

Emerging players on record are Neurotrack, Winterlight Labs and Posit Science (BrainHQ). Direct peers are Altoida, Linus Health, Cogstate, BrainCheck, Cambridge Cognition and Creyos (Cambridge Brain Sciences). Cerveau Technologies is listed as an others.

Does MoCA Cognition have an API?

No public API is recorded for MoCA Cognition.

What industry is MoCA Cognition in?

MoCA Cognition's product category is Cognitive Assessment Software. Its primary akta.pro industry code is HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits), with a secondary code of EDAGADAJ, Diagnostic & Adaptive Assessment Content (Skills/Readiness). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AlzintEncouraging earlier conversations about brain health: a case study on MoCA-XpressOADI published a case study highlighting MoCA Cognition's MoCA-XpressO digital self-assessment platform for cognitive health, which was launched in March 2024. The platform has collected data from over 150,000 completed tests, with approximately 40% of users from the US and 60% international, and early findings show over 85% of users found the tool helpful and 70% expressed willingness to discuss results with healthcare professionals. The case study suggests digital self-assessment tools may help normalize conversations about cognitive health and encourage earlier medical consultation.outsourcing-pharma.comuMotif teams Up with MoCA Cognition to enhance CNS research data captureuMotif partnered with MoCA Cognition to integrate cognitive assessments into its eCOA/ePRO platform for CNS research. The collaboration includes the MoCA test and the XpressO digital pre-screening tool, aiming to reduce screen fail rates and accelerate study timelines. Solutions are available for immediate deployment.PR NewswirePOTUS Cognitive Test Creators Introduce MoCA-XpressO for Public UseMoCA Cognition, the company behind the Montreal Cognitive Assessment (MoCA Test), has announced the US public release of its new XpressO by MoCA cognitive self-assessment app for browser, tablet, and smartphone. Validation studies demonstrated approximately 85% accuracy in predicting MoCA scores in the mild cognitive impairment range, with the app designed to address growing demand driven by aging populations, limited healthcare resources, and new FDA-approved Alzheimer's treatments that require early diagnosis.PR NewswirePresidents' Cognition and Appropriate Use of the MoCA TestMoCA Cognition, the company behind the Montreal Cognitive Assessment (MoCA Test), issued a statement reasserting its copyright and terms of use restrictions following widespread media coverage related to the presidential race. The company clarified that the MoCA Test is a copyrighted work that cannot be reproduced or distributed without express permission and is designed exclusively for use by trained healthcare professionals. MoCA Cognition also promoted its commercially available "XpressO by MoCA" app as a self-assessment alternative for the general public.PrwebuMotif and MoCA Cognition Bring Modern, Patient-Centric eCOA/ePRO, MoCA Test and New XpressO Mobile App to Clinical Trials, Real-World Studies for CNS-Related ConditionsuMotif and MoCA Cognition announced a collaboration to integrate the MoCA Test with uMotif's eCOA/ePRO platform for CNS-related clinical trials. The partnership aims to facilitate the capture of cognitive function data for sponsors and CROs, leveraging uMotif's patient-centric technology and MoCA's leading cognitive screening tool.